• Pol II Degradation and Transcription-Independent Cell Death

  2026-08-14

  The reference preprint separates RNA polymerase II loss from transcriptional shutdown as causes of cell death. Its findings suggest that depletion of hypophosphorylated Pol II can activate a regulated apoptotic program, providing a sharper framework for interpreting transcription-inhibitor experiments and apoptosis-focused cancer research.

• Pitavastatin (NK-104): In Vitro Guide

  2026-08-13

  Pitavastatin (NK-104) provides a defined HMG-CoA reductase inhibitor for laboratory studies of cholesterol biosynthesis, including cell-based assays relevant to cardiovascular and atherosclerosis research. The supplied dossier supports in vitro and biochemical use, but does not validate clinical application or direct in vivo animal use, and no directly matched paper evidence is assumed here.

• KR-12: Translational Design Beyond LL-37

  2026-08-13

  KR-12 is the minimal active fragment of human LL-37, combining membrane-directed antimicrobial activity with anti-biofilm, LPS-neutralizing, and immunomodulatory potential. This thought-leadership guide interprets the evidence, defines validation priorities, and shows how KR-12 (human) TFA can support more disciplined translational research.

• Viral RIPK3 Degradation and Inflammation

  2026-08-12

  Liu et al. identified a cowpox virus protein family, termed viral inducers of RIPK3 degradation, that recruits host SCF machinery to eliminate RIPK3 and reshape necroptosis-linked antiviral responses. The study connects vIRD activity with orthopoxvirus replication, inflammation, and mortality in genetically defined mouse models, providing a mechanistic framework for pathogen–host evolution.

• ABT-263 (Navitoclax) Experimental Workflow

  2026-08-12

  ABT-263 (Navitoclax) provides a high-affinity way to interrogate Bcl-2 family control of mitochondrial apoptosis in cancer and senescence models. This workflow connects dose-response apoptosis assays with a practical comparison of free compound and galactose-functionalized micelle delivery.

• Carrier-Platin Triggers Rapid ROS Cancer Cell Death

  2026-08-11

  Liu and colleagues developed carrier-platin, a platinum nanotherapeutic that confines ultrasmall platinum particles within a poly(amino acids) carrier to generate a rapid intracellular ROS burst. The resulting cancer cell death occurs within minutes, appears independent of DNA damage, and is distinct from classical apoptosis and ferroptosis, suggesting a preclinical strategy for addressing multidrug-resistant tumors.

• VP26, Actin–Myosin II, and Duck Enteritis Virus

  2026-08-11

  A 2025 study used VP26-centered co-immunoprecipitation proteomics to identify host cytoskeletal proteins associated with duck enteritis virus, then functionally linked the actin–myosin II network to viral proliferation. The work highlights MYH9 as a candidate host factor and provides a framework for testing cytoskeletal dependence with complementary chemical and genetic perturbations.

• CX-4945 (Silmitasertib) in Reliable Cell Assays

  2026-08-10

  This scenario-driven guide shows how CX-4945 (Silmitasertib), SKU A8330, can help researchers interpret viability, proliferation, apoptosis, and cell-cycle data through a CK2-centered experimental framework. It combines formulation guidance, mechanistic controls, assay troubleshooting, and evidence from cancer research to support more reproducible laboratory decisions.

• Roscovitine Workflows for CDK and Tumor Studies

  2026-08-09

  Roscovitine enables controlled dissection of CDK2, CDK5, and CDC2 signaling, reversible late-prophase arrest, and tumor-response mechanisms. This practical guide connects cell-cycle assays with radiotherapy–immunotherapy research while clearly separating established evidence from hypothesis-generating combination designs.

• AZD0156: A Pharmacology-First DDR Strategy

  2026-08-08

  AZD0156 is a selective ATM kinase inhibitor for studying DNA double-strand break signaling and treatment response. This pharmacology-first guide connects ATM biology with lessons from systematic kinase-inhibitor profiling to improve assay design and interpretation.

• AZD1480: A JAK2/STAT3 Assay Strategy

  2026-08-07

  AZD1480 is a potent JAK2 inhibitor for dissecting tumor-intrinsic STAT3 activation after IDO1 blockade. This guide translates single-cell evidence into compartment-resolved assays, pharmacology controls, and practical interpretation.

• Lypressin Acetate: Mechanistic Evidence and Clinical Utility

  2026-08-07

  Lypressin acetate is a natural vasopressin analog used in the treatment of diabetes insipidus. Its mechanism as a G protein-coupled receptor agonist enables potent antidiuretic and vasopressor activity. Recent data highlight its reproducible bioactivity and emerging antiviral applications.

• Central Circuits in Opioid-Induced Mechanical Hypersensitivi

  2026-08-06

  Yin et al. (2024) delineate a brain-to-spinal opioid pathway mediating mechanical opioid-induced hypersensitivity (OIH) and tolerance in mice. Their work clarifies the central mechanisms underlying morphine’s paradoxical effects on pain sensitivity, offering new targets for pain modulation research.

• IDO1 Inhibition Drives Tumor-Protective STAT3 Activation via

  2026-08-06

  This study reveals that pharmacological inhibition of IDO1, while enhancing antitumor immunity, paradoxically activates the tumor-intrinsic JAK2/STAT3 pathway through IL-6 secretion, leading to tumor-protective effects. The findings highlight the mechanistic basis for combining JAK2/STAT3 pathway inhibitors with IDO1 blockade to improve cancer immunotherapy outcomes.

• MDL 28170: Elevating Translational Neuroprotection Strategie

  2026-08-05

  Explore how MDL 28170, a selective calpain and cathepsin B inhibitor, advances neuroprotection research by bridging mechanistic insight with translational opportunity. Grounded in recent mechanistic studies and best practices, this thought-leadership piece guides researchers on leveraging MDL 28170 for reproducible apoptosis, neuroprotection, and ischemia-reperfusion injury models—delivering actionable workflow protocols, competitive positioning, and a forward-looking perspective.

8070 records 3/538 page Previous Next 12345 下5页 Last page